Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Operations
WAT logo

Waters Corp Transforms Into Life Sciences Giant With $16.8 Billion BDS Acquisition

WAT10-KFiling Date: 2/23/2026
Waters Corporation
Description

What this story covers

Waters Corporation's 10-K details its strategic evolution through the landmark $16.8 billion BDS acquisition. Despite merger costs impacting operating income, 7% sales growth and strong recurring revenue from pharma customers signal a successful pivot toward comprehensive diagnostic and bioprocess leadership.

Story snapshot

CompanyWaters Corporation
TickerWAT
VariantStandard detailed
Duration12:08
Filing type10-K
PeriodAnnual 2025
IndustryTechnology
Accession0001193125-26-062604
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in